Ad
LLY Short Information Eli Lilly and Company
Short Information | Eli Lilly and Company (NYSE:LLY)
| Twenty Trading Day Totals | |
|---|---|
| Total Shorted Volume | 474,842 |
| Total Actual Volume | 84,808,250 |
| Short Trends | |
|---|---|
| Cover Days | 20 |
| Short Days | 0 |
| No Change Days | 0 |
| Averages | |
|---|---|
| Average Short Volume | 23,742 |
| Average Short Percentage | 0.60% |
Is there a LLY Short Squeeze or Breakout about to happen?
See the LLY Short Analysis for free Sign up or Login
Powered by Squeeze Report
LLY Twenty Trading Day's Volume to Short Volume Chart
LLY Twenty Trading Day Price Chart
LLY Short Data Results Days
| Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
|---|---|---|---|---|---|---|---|
| 12-09-2024 | $823.7 | $803.58 | $823.7 | $801.28 | 3,135,970 | 11,326 | 0.36% |
| 12-06-2024 | $827.68 | $826.71 | $841 | $825.6901 | 3,047,127 | 16,701 | 0.55% |
| 12-05-2024 | $827.78 | $825.62 | $831.13 | $817.46 | 2,423,388 | 30,582 | 1.26% |
| 12-04-2024 | $828.1 | $829.84 | $846.4629 | $820.5 | 3,871,090 | 41,573 | 1.07% |
| 12-03-2024 | $802.93 | $813.33 | $817.13 | $801.61 | 2,782,067 | 20,395 | 0.73% |
| 12-02-2024 | $798.11 | $799.8 | $805.35 | $795.2201 | 2,895,629 | 8,784 | 0.3% |
| 11-29-2024 | $791.33 | $795.35 | $800.33 | $789.331 | 2,206,918 | 4,617 | 0.21% |
| 11-27-2024 | $788.12 | $788.19 | $794.83 | $780.3 | 2,714,656 | 26,312 | 0.97% |
| 11-26-2024 | $785.2 | $789.32 | $807 | $773.95 | 6,622,610 | 41,344 | 0.62% |
| 11-25-2024 | $750 | $755 | $755 | $740.01 | 5,690,465 | 17,506 | 0.31% |
| 11-22-2024 | $757.05 | $748.01 | $761.2799 | $745.0812 | 4,015,450 | 25,266 | 0.63% |
| 11-21-2024 | $746.12 | $749.92 | $752.9999 | $735 | 4,143,204 | 48,141 | 1.16% |
| 11-20-2024 | $735.785 | $753.41 | $757.37 | $735.46 | 5,158,855 | 25,416 | 0.49% |
| 11-19-2024 | $716.31 | $729.73 | $730 | $712.42 | 5,832,480 | 31,746 | 0.54% |
| 11-18-2024 | $733.19 | $727.2 | $734 | $711.4001 | 9,154,351 | 22,805 | 0.25% |
| 11-15-2024 | $775.19 | $746.2 | $777.98 | $744.2 | 7,334,562 | 31,834 | 0.43% |
| 11-14-2024 | $809.19 | $786.23 | $809.19 | $783.51 | 3,998,847 | 16,411 | 0.41% |
| 11-13-2024 | $820.32 | $811.81 | $829.105 | $811.29 | 3,059,268 | 21,717 | 0.71% |
| 11-12-2024 | $830.2 | $818.86 | $833.99 | $810.7201 | 3,378,563 | 16,168 | 0.48% |
| 11-11-2024 | $831.3 | $832.44 | $844 | $824.625 | 3,342,750 | 16,198 | 0.48% |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting PR Newswire Results from BRUIN CLL-321 show Lilly's pirtobrutinib reduced ...
-
Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase PR Newswire INDIANAPOLIS , Dec. 9, 2024 /PRNewswire/ -- Today, the board of directors of Eli Lilly and Company (NYSE: LLY) approved a new $15 billion share ...
-
CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® Parade PR Newswire Pro Football Hall of Famer Brian Dawkins joins the team to motivate those at risk for kidney disease to prioritize compl...